Grifols and CRB invest EUR 4 million in Mecwins technology

Grifols, through Progenika Biopharma, and CRB Inverbío undersign EUR 2 million of Mecwins’ capital increase each. The total investment of EUR 4 million will allow Mecwins to complete the introduction of the technology into the Life Sciences Market and to conduct clinical trials to demonstrate the diagnostic capabilities of its ultra-sensitive technology (a million times higher than that used in routine clinical practice).

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the Mecwins website.ContinueRead more